Table 2.

Multivariate Cox proportional hazards model for BRFS in association with percent of cells and cores with PTEN loss using threshold

Variable	BRFS in association with % of cells with PTEN loss				BRFS in association with % of cores with PTEN loss
	Training cohort		Validation cohort		Training cohort		Validation cohort
	HR (95% CI)	P *	HR (95% CI)	P *	HR (95% CI)	P *	HR (95% CI)	P *
Age, 1-unit increase, y	0.97 (0.94 to 0.99)	.04	1.05 (0.99 to 1.11)	.08	0.97 (0.94 to 1.00)	.046	1.04 (0.98 to 1.10)	.16
PSA, 1-unit increase	1.02 (1.00 to 1.05)	.05	1.00 (0.94 to 1.07)	.94	1.03 (1.00 to 1.05)	.04	0.99 (0.93 to 1.06)	.81
ERG, fusion vs no fusion	0.86 (0.59 to 1.24)	.41	0.74 (0.39 to 1.41)	.36	0.84 (0.58 to 1.23)	.38	0.82 (0.43 to 1.57)	.55
Grade groups (GG)
GG2 vs GG1	1.03 (0.64 to 1.66)	.91	1.67 (0.62 to 4.50)	.31	1.05 (0.65 to 1.69)	.85	1.96 (0.73 to 5.27)	.18
≥GG3 vs GG1	1.75 (1.09 to 2.82)	.02	2.19 (0.68 to 7.10)	.19	1.75 (1.09 to 2.82)	.02	2.48 (0.77 to 7.97)	.13
Extraprostatic extension, yes vs no	1.52 (1.01 to 2.29)	.04	1.69 (0.82 to 3.46)	.15	1.53 (1.01 to 2.29)	.04	1.66 (0.81 to 3.38)	.16
Seminal vesicle invasion, yes vs no	4.19 (2.40 to 7.33)	<.001	2.62 (0.98 to 7.00)	.05	4.21 (2.41 to 7.36)	<.001	2.21 (0.82 to 5.97)	.12
Surgical margin (SM), Yes vs no	2.40 (1.63 to 3.53)	<.001	2.14 (1.06 to 4.34)	.03	2.39 (1.63 to 3.52)	<.001	2.1 (1.05 to 4.20)	.03
PTEN loss (% cells)
Low (1%–65%) vs intact (0%)	1.61 (0.95 to 2.75)	.08	1.45 (0.70 to 3.01)	.32	1.96 (1.18 to 3.26)	.009	1.25 (0.48 to 3.28)	.64
High (>65%) vs intact (0%)	2.48 (1.59 to 3.87)	<.001	4.22 (2.01 to 8.83)	<.001	2.15 (1.36 to 3.42)	.001	2.75 (1.46 to 5.17)	.002

^*Two-sided log-rank test. BRFS = biochemical recurrence-free survival; CI = confidence interval; HR = hazard ratio; PSA = prostate-specific antigen; PTEN = phosphatase and tensin homolog.